Qtrex Quantum Ltd. · NASDAQ:QTEX
Qtrex Quantum — Inspira Technologies OXY B.H.N. — Investor Presentation (March 2022)
20 slides from Qtrex Quantum's investor presentation, Mar 31, 2022
Slide 1: 2021 Update
2021 Update INSPIC ss.
Slide 2: Highlights, Financial Summary, CEO Operational Summary, Core Technology, Photos, Financial Statements
H ighlig ht s F inanci a l S u mm a r y CEO O perati o n a l S u mm ar y Core Technology P hoto s F inanci a l S tate m ent s A ddition a l Infor m at i o n 03 04 0 5 0 8 11 18 19 2
Slide 3: Summary Highlights
O u r b u s i n e s s h a s s h o w n s t r o n g re s il i e nc e d u r i n g t h e s e un p re c e d e n t e d t i m e s . Despit e t h e challenges of Covid - 19 , w e proceeded with proprietary technological development and testing, while completing an Initial Public Offering on the Nasdaq Capit
Slide 4: Financial Summary
F I N A N C I A L 4 S U M M A R Y Capital Raising P r o f i t a b i l i t y Ca s h On July 16 , 2021 , Inspira completed the closing of its initial public offering of an aggregate of 2,909,091 ordinary shares ( “ IINN ” ) and 3,345,454 ( “ IINNW ” ) warrants to purchase ordinary shares. The gross pr
Slide 5: CEO Operational Summary
5 CEO O P E R A T I O N A L S U M M A R Y Dagi Ben - Noon, CEO, Director, and Co - Founder of Inspira Former Co - Founder, COO and Director of Nano Dimension Ltd. (Nasdaq: NNDN) “ Inspira targets to prevent the need for mechanical ventilation with Augmented Respiratory Technology, has already signed
Slide 6: Advancing product developments and patent filings
We have been highly focused on advancing product developments, including filing PCT(Patent Cooperation Treaty) patent applicatio ns for our flagship ART and Proprietary Method of Use, for Novel Dual Lumen Cannula Used for Blood Oxygenation as well as a patent application filed for a Supportive Devic
Slide 7: Scientific Advisory Board
Scientific Advisory Board (Joined as of January 2021 ) Prof. Daniel Brodie, MD, President of the Extracorporeal Life Support Organization (ELSO) and the chairman of the Executive Committee of the Internati ona l ECMO Network ( ECMONet ). Prof Brodie is also Section Chief for Critical Care within the
Slide 8: Core Technology
The plug - and - play disposable cartridge together with our autonomous self - priming of the entire blood circuit (Disposable cannula and respiratory support unit), potentially further reduces the need for a perfusionist , making it more suitable to extend deployment of ART from ICUs to General Med
Slide 9: Photos
PHOTOS Z inspira
Slide 10: New Facility - Ra'anana, Israel
N E W F A C I L I T Y - R A ’ A N A N A, I S R A E L 10
Slide 11: Inspira Lab Testing
I N S P I R A - L A B T E S T I N G 11
Slide 12: Financial Statements
FINANCIAL STATEMENTS y) inspira
Slide 13: Annual R&D, Marketing and Net Loss
13 Research and Development (R&D) Marketing Net Loss The total R&D expenses for the year ended December 31 , 2021 were $ 3.9 M, with the total expenses for the corresponding period in 2020 also totaling $ 3.9 M. However, in comparison to 2020 , in 2021 there was an increase in payroll and related ex
Slide 14: Q4 R&D, Marketing and Finance
Research and Development (R&D) 14 Marketing Finance R&D expenses for the three months ended December 31 , 2021 were $ 2.6 M compared to $ 1.2 M for the corresponding period in 2020 . The increase resulted primarily from an increase in payroll and related expenses, including share - based payment exp
Slide 15: Financial Balance Sheet Highlights
15 Cash & Cash Equivalents Financial Liabilities Cash & cash equivalents were $ 23.7 M as of December 31 , 2021 , compared to $ 496,000 as of December 31 , 2020 . The increase mainly reflects the proceeds from the IPO as well as proceeds from warrants exercises, less cash used in operati ons , durin
Slide 16: Statements of Financial Position - Assets
S T A T E M E N T S O F F I N A N C I A L P O S I T I O N (U .S. D o l l a r s I n t h o u s a n d s) 16 ART – Respiratory Support System TM December 31, December 31, 2021 2020 ASSETS Current Assets: Cash and cash equivalents 23,749 496 Other accounts receivable 759 188 Total current assets 24,508 6
Slide 17: Statements of Financial Position - Liabilities and Equity
17 S T A T E M E N T S O F F I N A N C I A L P O S I T I O N (U .S. D o l l a r s I n t h o u s a n d s) Dual Lumen Cannula December 31, December 31, 2021 2020 LIABILITIES AND SHAREHOLDERS’ EQUITY Current Liabilities: Trade accounts payables 93 3 Other accounts payable 725 549 Lease liabilities 281
Slide 18: Statements of Comprehensive Loss
18 S T A T E M E N T S O F F I N A N C I A L P O S I T I O N (U .S. D o l l a r s I n t h o u s a n d s) Oxygenator Initiation System Pump ART - Hemo Protective System For the Year Ended December 31, For the Three-Month Period Ended December 31, 2021 2020 2021 2020 Research and development expenses
Slide 19: Additional Information and Forward-Looking Statements
A D D I T I O N A L I N F O R M A T I O N W E B S I T E I N F O R M A T I O N https://inspira - technologies.com/ F O R W A R D - L O O K I N G S TA T E M E N T S 19 This document of InspiraTM Technologies Oxy B.H.N. Ltd. (Inspira Technologies or the “ Company ” ) contains “ forward - looking statem
Slide 20: INS PIC ee.
INS PIC ee.
Inspira Technologies OXY B.H.N. — Investor Presentation (March 2022) on 6ix